On June 14, Gelonhui reported that an investor asked Chongqing Zhifei Biological Products (300122.SZ) on the investor interaction platform, "May I ask at what stage the company's RSV vaccine research and development is at?" The company replied that the respiratory syncytial virus (RSV) vaccine in its research and development pipeline is currently in the preclinical stage.
智飞生物(300122.SZ)：研发管线内的呼吸道合胞病毒(RSV)疫苗目前处于临床前研究阶段
Chongqing Zhifei Biological Products (300122.SZ): Respiratory syncytial virus (RSV) vaccine in the R&D pipeline is currently in the preclinical research stage.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.